Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users

References

• Adkins, J. E., W. Boyer, and C. R. McCurdy. 2011. Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Current Topics in Medicinal Chemistry 11 (9):1165–75.
   PubMed Web of Science ®Google Scholar
• Ahmad, K., and Z. Aziz. 2012. Mitragyna speciosa use in the northern states of Malaysia: A cross-sectional study. Journal of Ethnopharmacology 141:446–50. doi:10.1016/j.jep.2012.03.009.
   PubMed Web of Science ®Google Scholar
• American Kratom Association. 2019. Home. https://www.americankratom.org/ (accessed February 5, 2019).
   Google Scholar
• Anwar, M., R. Law, and J. Schier. 2016. Notes from the field: Kratom (Mitragyna speciose) exposures reported to poison control centers-United States, 2010–2015. MMWR Morbidity and Mortality Weekly Report 65:748–49. doi:10.15585/mmwr.mm6529a4.
   PubMed Web of Science ®Google Scholar
• Aronowitz, S. V., and J. Laurent. 2016. Screaming behind a door: The experiences of individuals incarcerated without medication-assisted treatment. Journal of Correctional Health Care 22:98–108. doi:10.1177/1078345816634079.
   PubMed Web of Science ®Google Scholar
• Assanangkornchai, S., A. Muekthong, N. Sam-Angsri, and U. Pattanasattayawong. 2007. The use of Mitragynine speciosa (“Krathom”), an addictive plant, in Thailand. Substance Use and Misuse 42:2145–57. doi:10.1080/10826080701205869.
   PubMed Web of Science ®Google Scholar
• Basiliere, S., K. Bryand, and S. Kerrigan. 2018. Identification of five Mitragyna alkaloids in urine using liquid chromatography-quadrupole/time of flight mass spectrometry. Journal of Chromatography B 1080:11–19. doi:10.1016/j.jchromb.2018.02.010.
   PubMed Web of Science ®Google Scholar
• Boyer, E. W., K. M. Babu, J. E. Adkins, C. R. McCurdy, and J. H. Halpern. 2008. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction 103:1048–50. doi:10.1111/j.1360-0443.2008.02209.x.
   PubMed Web of Science ®Google Scholar
• Brady, K. T., J. L. McCauley, and S. E. Back. 2015. Prescription opioid misuse, abuse, and treatment in the United States: An update. American Journal of Psychiatry 173:18–26. doi:10.1176/appi.ajp.2015.15020262.
   PubMed Web of Science ®Google Scholar
• Brinkley-Rubinstein, L., N. Zaller, S. Martino, D. H. Cloud, E. McCauley, A. Heise, and D. Seal. 2018. Criminal justice continuum for opioid users at risk of overdose. Addictive Behaviors. doi:10.1016/j.addbeh.2018.02.024.
   PubMed Web of Science ®Google Scholar
• Brown, P. N., J. A. Lund, and S. J. Murch. 2017. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom. Journal of Ethnopharmacology 202:302–25. doi:10.1016/j.jep.2017.03.020.
   PubMed Web of Science ®Google Scholar
• Carroll, J. J., B. D. Marshall, J. D. Rich, and T. C. Green. 2017. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. International Journal of Drug Policy 46:136–45. doi:10.1016/j.drugpo.2017.05.023.
   PubMed Web of Science ®Google Scholar
• Castillo, O. 2018. Kratom crackdown: How the DEA abused its emergency scheduling authority under the Controlled Substances Act. University of Miami Law Review 72:972–1024.
   Google Scholar
• Centers for Disease Control and Prevention. 2017a. Annual surveillance report of drug-related risks and outcomes — United States, 2017. Surveillance special report 1. Centers for disease control and prevention, U.S. department of health and human services. Accessed April 1, 2018. https://www.cdc.gov/drugoverdose/pdf/pubs/2017cdc-drug-surveillance-report.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. 2017b. Drug overdose death data | Drug overdose | CDC injury center. Accessed April 11, 2018. https://www.cdc.gov/drugoverdose/data/statedeaths.html.
   Google Scholar
• Centers for Disease Control and Prevention. 2018. Quality improvement and care coordination: Implementing the CDC guideline for prescribing opioids for chronic pain. Atlanta, GA: National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention.
   Google Scholar
• Chien, G. C. C., C. Odonkor, and P. Amorapanth. 2017. Is Kratom the new ‘legal high’ on the block? The case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician 20:E195–E198.
   PubMed Web of Science ®Google Scholar
• Cicero, T. J., M. S. Ellis, and H. D. Chilcoat. 2018. Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2018.09.007.
   Web of Science ®Google Scholar
• Compton, W. M., C. M. Jones, and G. T. Baldwin. 2016. Relationship between nonmedical prescription-opioid use and heroin use. The New England Journal of Medicine 374:154–63. doi:10.1056/NEJMra1508490.
   PubMed Web of Science ®Google Scholar
• Daniulaityte, R., R. Falck, and R. G. Carlson. 2012. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug and Alcohol Dependence 122:201–07. doi:10.1016/j.drugalcdep.2011.09.029.
   PubMed Web of Science ®Google Scholar
• Darke, S. 1998. Self-report among injecting drug users: A review. Drug and Alcohol Dependence 3:253–63. doi:10.1016/S0376-8716(98)00028-3.
   Web of Science ®Google Scholar
• Dart, R. C., H. L. Surratt, T. J. Cicero, M. W. Parrino, S. G. Severtson, B. Bucher-Bartelson, and J. L. Green. 2015. Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine 372:241–48. doi:10.1056/NEJMsa1406143.
   PubMed Web of Science ®Google Scholar
• Denis, C., M. Fatséas, V. Beltran, C. Bonnet, S. Picard, I. Combourieu, J. Daulouède, and M. Auriacombe. 2012. Validity of the self-reported drug use section of the Addiction Severity Index and associated factors used under naturalistic conditions. Substance Use and Misuse 47:356–63. doi:10.3109/10826084.2011.640732.
   PubMed Web of Science ®Google Scholar
• Department of Justice. 2016. Memorandum: Department of justice strategy to combat opioid epidemic. https://www.justice.gov/opioidawareness/file/896776/download.
   Google Scholar
• Dolengevich-Segal, H., B. Rodríguez-Salgado, J. Gómez-Arnau, and D. Sánchez-Mateos. 2017. An approach to the new psychoactive drugs phenomenon. Salud Mental 40:71–82. doi:10.17711/SM.0185-3325.2017.010.
   Web of Science ®Google Scholar
• Domingo, O., G. Roider, A. Stöver, M. Graw, F. Musshoff, H. Sachs, and W. Bicker. 2017. Mitragynine concentrations in two fatalities. Forensic Science International 271:e1–e7. doi:10.1016/j.forsciint.2016.12.020.
   PubMed Web of Science ®Google Scholar
• Dyer, K. R., J. M. White, D. J. Foster, F. Bochner, A. Menelaou, and A. A. Somogyi. 2001. The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology 21:78–84.
   PubMed Web of Science ®Google Scholar
• Epstein, D. H., M. Heilig, and Y. Shaham. 2018. Science-based actions can help address the opioid crisis. Trends in Pharmacological Sciences 39 (11):911–916. doi:10.1016/j.tips.2018.06.002.
   PubMed Web of Science ®Google Scholar
• Faryar, K. A., C. L. Freeman, A. K. Persaud, S. P. Furmanek, B. E. Guinn, W. A. Mattingly, and M. R. Huecker. 2017. The effects of Kentucky’s comprehensive opioid legislation on patients presenting with prescription opioid or heroin abuse to one urban emergency department. Journal of Emergency Medicine 53:805–14. doi:10.1016/j.jemermed.2017.08.066.
   PubMed Web of Science ®Google Scholar
• Federal Register: The Daily Journal of the United States Government. 2016, October 13. Withdrawal of notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into schedule I. https://www.federalregister.gov/documents/2016/10/13/2016-24659/withdrawal-of-notice-of-intent-to-temporarily-place-mitragynine-and-7-hydroxymitragynine-into.
   Google Scholar
• Fluyau, D., and N. Revadigar. 2017. Biochemical benefits, diagnosis, and clinical risks evaluation of Kratom. Frontiers in Psychiatry 8:62. doi:10.3389/fpsyt.2017.00297.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). 2018a. FDA and kratom [Internet]. US food and drug administration home page. https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm584952.htm.
   Google Scholar
• Food and Drug Administration (FDA). 2018b. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse [Internet]. US Food and Drug Administration Home Page. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm595622.htm.
   Google Scholar
• Fox, A. D., J. Maradiaga, L. Weiss, J. Sanchez, J. L. Starrels, and C. O. Cunningham. 2015. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: A qualitative study of the perceptions of former inmates with opioid use disorder. Addiction Science & Clinical Practice 10:2. doi:10.1186/s13722-014-0023-0.
   PubMed Web of Science ®Google Scholar
• Furst, R. T. 2014. Diffusion and diversion of suboxone: An exploration of illicit street opioid selling. Journal of Addictive Diseases 33:177–86. doi:10.1080/10550887.2014.950030.
   PubMed Web of Science ®Google Scholar
• Griffin, O. H., III. 2014. The role of the United States supreme court in shaping federal drug policy. American Journal of Criminal Justice 39:660–79. doi:10.1007/s12103-013-9224-4.
   Google Scholar
• Griffin, O. H., III, J. A. Daniels, and E. A. Gardner. 2016. Do you get what you paid for? An examination of products advertised as kratom. Journal of Psychoactive Drugs 48:330–35. doi:10.1080/02791072.2016.1229876.
   PubMed Web of Science ®Google Scholar
• Griffin, O. H., III, and M. E. Webb. 2018. The scheduling of kratom and selective use of data. Journal of Psychoactive Drugs 50:114–20. doi:10.1080/02791072.2017.1371363.
   PubMed Web of Science ®Google Scholar
• Grundmann, O. 2017. Patterns of Kratom use and health impact in the US—Results from an online survey. Drug and Alcohol Dependence 176:63–70. doi:10.1016/j.drugalcdep.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Grundmann, O., P. N. Brown, J. Henningfield, M. Swogger, and Z. Walsh. 2018. The therapeutic potential of kratom. Addiction 113:1951–53. doi:10.1111/add.14371.
   PubMed Web of Science ®Google Scholar
• Hall, M. T., C. G. Leukefeld, and J. R. Havens. 2013. Factors associated with high-frequency illicit methadone use among rural Appalachian drug users. American Journal of Drug and Alcohol Abuse 39:241–46. doi:10.3109/00952990.2013.805761.
   PubMed Web of Science ®Google Scholar
• Haron, M., and S. Ismail. 2015. Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5ʹ-diphospho-glucuronosyltransferase isoforms. Pharmacognosy Research 7:341. doi:10.4103/0974-8490.159580.
   Web of Science ®Google Scholar
• Hassan, Z., M. Muzaimi, V. Navaratnam, N. H. Yusoff, F. W. Suhaimi, R. Vadivelu, B. K. Vicknasingam, D. Amato, S. von Hörsten, N. I. Ismail, et al. 2013. From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience & Biobehavioral Reviews 37:138–51. doi:10.1016/j.neubiorev.2012.11.012.
   PubMed Web of Science ®Google Scholar
• Havens, J. R., C. G. Leukefeld, A. M. DeVeaugh-Geiss, P. Coplan, and H. D. Chilcoat. 2014. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug and Alcohol Dependence 139:9–17. doi:10.1016/j.drugalcdep.2014.02.018.
   PubMed Web of Science ®Google Scholar
• Hedegaard, H., M. Warner, and A. M. Miniño. 2017. Drug overdose deaths in the United States, 1999–2016. NCHS Data Rief, No 294, National Center for Health Statistics, Hyattsville, MD.
   Google Scholar
• Hemby, S. E., S. McIntosh, F. Leon, S. J. Cutler, and C. R. McCurdy. 2018. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology. doi:10.1111/adb.12639.
   PubMed Web of Science ®Google Scholar
• Henningfield, J. E., R. V. Fant, and D. W. Wang. 2018. The abuse potential of kratom according the 8 factors of the controlled substances act: Implications for regulation and research. Psychopharmacology 235:1–17.
   PubMed Web of Science ®Google Scholar
• Ismail, N. I. W., N. Jayabalan, S. M. Mansor, C. P. Müller, and M. Muzaimi. 2016. Chronic mitragynine (kratom) enhances punishment resistance in natural reward seeking and impairs place learning in mice. Addiction Biology 22:967–967. doi:10.1111/adb.12385.
   PubMed Web of Science ®Google Scholar
• Jalal, H., J. M. Buchanich, M. S. Roberts, L. C. Balmert, K. Zhang, and D. S. Burke. 2018. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361:eaau1184. doi:10.1126/science.aau1184.
   PubMed Web of Science ®Google Scholar
• Jarvis, B. P., A. F. Holtyn, S. Subramaniam, D. A. Tompkins, E. A. Oga, G. E. Bigelow, and K. Silverman. 2018. Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction. doi:10.1111/add.14180.
   Web of Science ®Google Scholar
• Jayadeva, V., A. Bunnag, R. Meyen, and I. Fernando. 2017. Kratom (Mitragyna speciosa) use in a veteran with chronic pain. American Journal of Psychiatry Residents’ Journal 12:13–15. doi:10.1176/appi.ajp-rj.2017.120305.
   Google Scholar
• Johnson, B., and T. Richert. 2014. Diversion of methadone and buprenorphine from opioid substitution treatment: A staff perspective. Journal of Psychoactive Drugs 46:427–35. doi:10.1080/02791072.2014.960109.
   PubMed Web of Science ®Google Scholar
• Jonas, A. B., A. M. Young, C. B. Oser, C. G. Leukefeld, and J. R. Havens. 2012. OxyContin® as currency: OxyContin® use and increased social capital among rural Appalachian drug users. Social Science and Medicine 74:1602–09. doi:10.1016/j.socscimed.2011.12.053.
   PubMed Web of Science ®Google Scholar
• Jones, E. B. 2018. Medication-assisted opioid treatment prescribers in federally qualified health centers: Capacity lags in rural areas. The Journal of Rural Health 34:14–22. doi:10.1111/jrh.12260.
   PubMed Web of Science ®Google Scholar
• Kanouse, A. B., and P. Compton. 2015. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. Journal of Pain & Palliative Care Pharmacotherapy 29:102–14. doi:10.3109/15360288.2015.1037521.
   PubMedGoogle Scholar
• Kentucky Cabinet for Health and Family Services. 2018. Kentucky all schedule prescription electronic reporting - cabinet for health and family services. https://chfs.ky.gov/agencies/os/oig/dai/deppb/Pages/kasper.aspx.
   Google Scholar
• Kentucky Department of Corrections. 2018. Substance abuse treatment modalities - department of corrections. https://corrections.ky.gov/Divisions/sap/Pages/modalities.aspx.
   Google Scholar
• Kentucky Office of Drug Control Policy. 2016. 2016 overdose fatality report. https://odcp.ky.gov/Documents/2016%20ODCP%20Overdose%20Fatality%20Report%20Final.pdf.
   Google Scholar
• Khanna, I. K., and S. Pillarisetti. 2015. Buprenorphine–An attractive opioid with underutilized potential in treatment of chronic pain. Journal of Pain Research 8:859.
   PubMed Web of Science ®Google Scholar
• Kolodny, A., D. T. Courtwright, C. S. Hwang, P. Kreiner, J. L. Eadie, T. W. Clark, and G. C. Alexander. 2015. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annual Review of Public Health 36:559–74. doi:10.1146/annurev-publhealth-031914-122957.
   PubMed Web of Science ®Google Scholar
• Kronstrand, R., M. Roman, G. Thelander, and A. Eriksson. 2011. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. Journal of Analytical Toxicology 35:242–47.
   PubMed Web of Science ®Google Scholar
• Kruegel, A. C., and O. Grundmann. 2018. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology 134:108–20. doi:10.1016/j.neuropharm.2017.08.026.
   PubMed Web of Science ®Google Scholar
• Lanier, R. K., R. V. Fant, E. Cone, and J. Henningfield. 2017. Assessment of the abuse potential and benefits of Kratom and its Mitragynine alkaloids: Implications for regulation. Drug and Alcohol Dependence 171:e114. doi:10.1016/j.drugalcdep.2016.08.317.
   Web of Science ®Google Scholar
• Likhitsathian, S., W. Jiraporncharoen, A. Aramrattana, C. Angkurawaranon, M. Srisurapanont, K. Thaikla, and R. Jarubenja. 2018. Polydrug use among kratom users: Findings from the 2011 Thailand National Household Survey. Journal of Substance Use 23:1–6.
   Web of Science ®Google Scholar
• Lin, H. C., Z. Wang, C. Boyd, L. Simoni-Wastila, and A. Buu. 2018. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addictive Behaviors 76:348–54. doi:10.1016/j.addbeh.2017.08.032.
   PubMed Web of Science ®Google Scholar
• Lofwall, M. R., and J. R. Havens. 2012. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug and Alcohol Dependence 126:379–83. doi:10.1016/j.drugalcdep.2012.05.025.
   PubMed Web of Science ®Google Scholar
• Luu, H., S. Slavova, P. R. Freeman, M. Lofwall, S. Browning, and H. Bush. 2018. Trends and patterns of opioid analgesic prescribing: Regional and Rural-urban variations in Kentucky from 2012 to 2015. The Journal of Rural Health35:97–107.
   Google Scholar
• Lydecker, A. G., A. Sharma, C. R. McCurdy, B. A. Avery, K. M. Babu, and E. W. Boyer. 2016. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. Journal of Medical Toxicology 12:341–49. doi:10.1007/s13181-016-0588-y.
   PubMed Web of Science ®Google Scholar
• Lydecker, A. G., M. D. Zuckkerman, J. B. Hack, B. Becker, J. K. Cherkes, E. W. Boyer, and K. M. Babu. 2017. Intravenous kratom use in a patient with opioid dependence. Journal of Toxicology and Pharmacology 1:3.
   Google Scholar
• Madras, B. K. 2018. The president’s commission on combating drug addiction and the opioid crisis: Origins and recommendations. Clinical Pharmacology & Therapeutics 103:943–45. doi:10.1002/cpt.1050.
   PubMed Web of Science ®Google Scholar
• Makary, M. A., H. N. Overton, and P. Wang. 2017. Overprescribing is major contributor to opioid crisis. BMJ e359.
   Google Scholar
• Manglik, A., H. Lin, D. K. Aryal, J. D. McCorvy, D. Dengler, G. Corder, and X. P. Huang. 2016. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185. doi:10.1038/nature19112.
   PubMed Web of Science ®Google Scholar
• Marshall, B. D., M. S. Krieger, J. L. Yedinak, P. Ogera, P. Banerjee, N. E. Alexander-Scott, and T. C. Green. 2017. Epidemiology of fentanyl-involved drug overdose deaths: A geospatial retrospective study in Rhode Island, USA. International Journal of Drug Policy 46:130–35. doi:10.1016/j.drugpo.2017.05.029.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K. 2006. Pharmacological studies on 7-Hydroxymitragynine, isolated from the Thai herbal medicine Mitragyna speciosa: Discovery of an orally active opioid analgesic. Tokyo: Department of Molecular Pharmacology and Pharmacotherapeutics, Graduate School of Pharmaceutical Sciences, Chiba University.
   Google Scholar
• Matsumoto, K., M. Mizowaki, T. Suchitra, Y. Murakami, H. Takayama, S. I. Sakai, N. Aimi, H. Watanabe. 1996. Central antinociceptive effects of mitragynine in mice: Contribution of descending noradrenergic and serotonergic systems. European Journal of Pharmacology 317:75–81.
   PubMed Web of Science ®Google Scholar
• McCarthy, M. 2017. How inappropriate prescribing prompted the opioid addiction ravaging small town America. BMJ 359:j4730.
   PubMed Web of Science ®Google Scholar
• Merrall, E. L., A. Kariminia, I. A. Binswanger, M. S. Hobbs, M. Farrell, J. Marsden, S. J. Hutchinson, S. M. Bird. 2010. Meta-analysis of drug-related deaths soon after release from prison. Addiction 105:1545–54. doi:10.1111/j.1360-0443.2010.02990.x.
   PubMed Web of Science ®Google Scholar
• Moody, L. N., E. Satterwhite, and W. K. Bickel. 2017. Substance use in rural Central Appalachia: Current status and treatment considerations. Journal of Rural Mental Health 41:123. doi:10.1037/rmh0000064.
   Google Scholar
• National Institutes of Health. 2018, July 5. In the news: Kratom (Mitragyna speciosa). https://nccih.nih.gov/news/kratom.
   Google Scholar
• Nelsen, J. L., J. Lapoint, M. J. Hodgman, and K. M. Aldous. 2010. Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. Journal of Medical Toxicology 6:424–26. doi:10.1007/s13181-010-0079-5.
   PubMedGoogle Scholar
• Pacula, R. L., and D. Powell. 2018. A supply side perspective on the opioid crisis. Journal of Policy Analysis and Management 37:438–46. doi:10.1002/pam.22049.
   Web of Science ®Google Scholar
• Pollini, R. A., C. J. Banta-Green, J. Cuevas-Mota, M. Metzner, E. Teshale, and R. S. Garfein. 2011. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Substance Abuse and Rehabilitation 2:173. doi:10.2147/SAR.S24800.
   PubMedGoogle Scholar
• Porter-Stransky, K. A., and D. Weinshenker. 2017. Arresting the development of addiction: The role of β-arrestin 2 in drug abuse. Journal of Pharmacology and Experimental Therapeutics 361:341–48. doi:10.1124/jpet.117.240622.
   PubMed Web of Science ®Google Scholar
• Powell, D., and R. L. Pacula. 2017. Prescription opiates and opioid abuse: Regulatory efforts to limit diversion from medical markets to black markets in the United States. In Dual markets, ed. E. Savona, M. Kleiman, F. Calderoni, 37–54. Cham: Springer.
   Google Scholar
• Prozialeck, W. C., J. K. Jivan, and S. V. Andurkar. 2012. Pharmacology of kratom: An emerging botanical agent with stimulant, analgesic and opioid-like effects. The Journal of the American Osteopathic Association 112:792–99.
   PubMedGoogle Scholar
• Saingam, D., S. Assanangkornchai, A. F. Geater, and Q. Balthip. 2013. Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: A qualitative study. International Journal of Drug Policy 24:351–58. doi:10.1016/j.drugpo.2012.09.004.
   PubMed Web of Science ®Google Scholar
• Saingam, D., S. Assanangkornchai, A. F. Geater, and S. Lerkiatbundit. 2016. Factor analytical investigation of krathom (Mitragyna speciosa Korth.) withdrawal syndrome in Thailand. Journal of Psychoactive Drugs 48:78–85. doi:10.1080/02791072.2016.1156791.
   Web of Science ®Google Scholar
• Singh, D., C. P. Müller, B. K. Vicknasingam, and S. M. Mansor. 2015. Social functioning of Kratom (Mitragyna speciosa) users in Malaysia. Journal of Psychoactive Drugs 47:125–31. doi:10.1080/02791072.2015.1012610.
   PubMed Web of Science ®Google Scholar
• Singh, D., C. P. Müller, V. Murugaiyah, S. B. S. Hamid, B. K. Vicknasingam, B. Avery, and S. M. Mansor. 2018a. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. Journal of Ethnopharmacology 214:197–206. doi:10.1016/j.jep.2017.12.017.
   PubMed Web of Science ®Google Scholar
• Singh, D., S. Narayanan, and B. Vicknasingam. 2016. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Research Bulletin 126:41–46. doi:10.1016/j.brainresbull.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Singh, D., S. Narayanan, B. Vicknasingam, O. Corazza, R. Santacroce, and A. Roman‐Urrestarazu. 2017. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Human Psychopharmacology: Clinical and Experimental 32:e2582. doi:10.1002/hup.v32.3.
   Web of Science ®Google Scholar
• Singh, D., S. Narayanan, C. P. Müller, M. T. Swogger, A. A. Rahim, M. F. I. Leong Bin Abdullah, and B. K. Vicknasingam. 2018c. Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawal symptoms. Journal of Psychoactive Drugs 50:1–6.
   Web of Science ®Google Scholar
• Singh, D., V. Murugaiyah, S. B. S. Hamid, V. Kasinather, M. S. A. Chan, E. T. W. Ho, and S. M. Mansor. 2018b. Assessment of gonadotropins and testosterone hormone levels in regular mitragyna speciosa (Korth.) users. Journal of Ethnopharmacology 221:30–36. doi:10.1016/j.jep.2018.04.005.
   PubMed Web of Science ®Google Scholar
• Slavova, S., J. F. Costich, T. L. Bunn, H. Luu, M. Singleton, S. L. Hargrove, J. S. Triplett, D. Quesinberry, W. Ralston, V. Ingram. 2017b. Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance. International Journal of Drug Policy 46:120–29. doi:10.1016/j.drugpo.2017.05.051.
   PubMed Web of Science ®Google Scholar
• Slavova, S., T. L. Bunn, S. L. Hargrove, T. Corey, and V. Ingram. 2017a. Linking death certificates, postmortem toxicology, and prescription history data for better identification of populations at increased risk for drug intoxication deaths. Pharmaceutical Medicine 31:155–65. doi:10.1007/s40290-017-0185-7.
   Web of Science ®Google Scholar
• Smid, M. C., J. E. Charles, A. J. Gordon, and T. E. Wright. 2018. Use of Kratom, an opioid-like traditional herb, in pregnancy. Obstetrics & Gynecology 132 (4):926–28. doi:10.1097/AOG.0000000000002871.
   PubMed Web of Science ®Google Scholar
• Smith, K. E., and T. Lawson. 2017. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug and Alcohol Dependence 180:340–48. doi:10.1016/j.drugalcdep.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Staton, M., G. Ciciurkaite, J. Havens, M. Tillson, C. Leukefeld, M. Webster, and B. Peteet. 2018. Correlates of injection drug use among rural Appalachian women. The Journal of Rural Health 34:31–41. doi:10.1111/jrh.12256.
   PubMed Web of Science ®Google Scholar
• Staton-Tindall, M., J. M. Webster, C. B. Oser, J. R. Havens, and C. G. Leukefeld. 2015. Drug use, hepatitis C, and service availability: Perspectives of incarcerated rural women. Social Work in Public Health 30:385–96. doi:10.1080/19371918.2015.1021024.
   PubMed Web of Science ®Google Scholar
• Substance Abuse Mental Health Services Administration. 2018. Buprenorphine treatment practitioner locator | SAMHSA - Substance Abuse and Mental Health Services Administration. Accessed October 12, 2018. https://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator.
   Google Scholar
• Suhaimi, F. W., N. H. Yusoff, R. Hassan, S. M. Mansor, V. Navaratnam, C. P. Müller, and Z. Hassan. 2016. Neurobiology of Kratom and its main alkaloid mitragynine. Brain Research Bulletin 126:29–40. doi:10.1016/j.brainresbull.2016.03.015.
   PubMed Web of Science ®Google Scholar
• Swogger, M. T., E. Hart, F. Erowid, E. Erowid, N. Trabold, K. Yee, A. Kimberly, B. A. Parkhurst, M. Brittany, B. S. Priddy, et al. 2015. Experiences of kratom users: A qualitative analysis. Journal of Psychoactive Drugs 47:360–67. doi:10.1080/02791072.2015.1096434.
   PubMed Web of Science ®Google Scholar
• Takayama, H., H. Ishikawa, M. Kurihara, M. Kitajima, N. Aimi, D. Ponglux, F. Koyama, K. Matsumoto, T. Moriyama, L. T. Yamamoto, et al. 2002. Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: Discovery of opioid agonists structurally different from other opioid ligands. Journal of Medicinal Chemistry 45:1949–56.
   PubMed Web of Science ®Google Scholar
• Tanguay, P. 2011. Kratom in Thailand. SSRN 1908849.
   Google Scholar
• Tatum, W. O., T. F. Hasan, E. E. Coonan, and C. P. Smelick. 2018. Recurrent seizures from chronic kratom use, an atypical herbal opioid. Epilepsy & Behavior Case Reports 10:18–20. doi:10.1016/j.ebcr.2018.04.002.
   PubMed Web of Science ®Google Scholar
• Tayabali, K., C. Bolzon, P. Foster, J. Patel, and M. O. Kalim. 2018. Kratom: A dangerous player in the opioid crisis. Journal of Community Hospital Internal Medicine Perspectives 8:107–10. doi:10.1080/20009666.2018.1468693.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Agriculture. 2013. Measuring rurality: Rural-urban continuum codes. United States Department of Agriculture Economic Research Service website https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/documentation/.
   Google Scholar
• Vicknasingam, B., S. Narayanan, G. T. Beng, and S. M. Mansor. 2010. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. International Journal of Drug Policy 4:283–88. doi:10.1016/j.drugpo.2009.12.003.
   Web of Science ®Google Scholar
• Walker, R., T. K. Logan, Q. T. Chipley, and J. Miller. 2018. Characteristics and experiences of buprenorphine-naloxone use among polysubstance users. American Journal of Drug Alcohol Abuse 44:595–603.
   PubMed Web of Science ®Google Scholar
• Walsh, S. L., K. L. Preston, M. L. Stitzer, E. J. Cone, and G. E. Bigelow. 1994. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics 55:569–80. doi:10.1038/clpt.1994.71.
   PubMed Web of Science ®Google Scholar
• Walter, C., C. Knothe, and J. Lötsch. 2016. Abuse-deterrent opioid formulations: Pharmacokinetic and pharmacodynamic considerations. Clinical Pharmacokinetics 55:751–67. doi:10.1007/s40262-015-0362-3.
   PubMed Web of Science ®Google Scholar
• Warner, M. L., N. C. Kaufman, and O. Grundmann. 2016. The pharmacology and toxicology of kratom: From traditional herb to drug of abuse. International Journal of Legal Medicine 130:127–38. doi:10.1007/s00414-015-1279-y.
   PubMed Web of Science ®Google Scholar
• Wiecko, F. M., W. E. Thompson, and B. P. Parham. 2017. A high by any other name: Exploring the motivations for consumption of “legal highs”. Deviant Behavior 38:549–60. doi:10.1080/01639625.2016.1197034.
   Web of Science ®Google Scholar
• Yeo, A. K., C. Chan, and K. Chia. 2006. Complications relating to intravenous buprenorphine abuse: A single institution case series. Annals of the Academy of Medicine Singapore 35:487.
   PubMed Web of Science ®Google Scholar
• Yokell, M. A., N. D. Zaller, T. C. Green, M. McKenzie, and J. D. Rich. 2012. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose. Journal of Opioid Management 8:63. doi:10.5055/jom.2012.0098.
   PubMedGoogle Scholar
• Zanis, D. A., A. T. McLellan, and M. Randall. 1994. Can you trust patient self-reports of drug use during treatment? Drug and Alcohol Dependence 35:127–32. doi:10.1016/0376-8716(94)90119-8.
   PubMed Web of Science ®Google Scholar
• Zibbell, J. E., K. Iqbal, R. C. Patel, A. Suryaprasad, K. J. Sanders, L. Moore-Moravian, and D. Holtzman. 2015. Increases in hepatitis C virus infection related to injection drug use among persons aged≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. Morbidity Mortality Weekly Report 64:453–58.
   PubMed Web of Science ®Google Scholar